Ipravent Inhaler (Ipratropium Bromide)

Ipratropium bromide works by competitively blocking muscarinic M3 receptors on airway smooth muscle. By preventing acetylcholine from binding to these receptors, it inhibits bronchoconstriction, leading to relaxation of the bronchial muscles and widened airways. This localized action improves airflow and reduces resistance in patients with obstructive lung diseases.

The prescribed dose of Ipravent Inhaler is determined by the treating physician based on the individual’s condition, severity, and response to therapy. Typical regimens involve one or more inhalations several times daily, but exact dosing instructions, including the number of puffs per administration, must be obtained from the prescriber’s order.

Safety data for ipratropium bromide in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Healthcare providers should consider the potential benefits against possible risks before prescribing to pregnant or nursing women, and the decision should be made on a case‑by‑case basis.

To place an order, visit the product page on gnhindia.com and submit an enquiry specifying the required quantity of Ipravent Inhaler. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including any cold‑chain requirements—and necessary import documentation.

Ipravent Inhaler delivers an anticholinergic agent, whereas β2‑agonists such as albuterol act via adrenergic pathways. Ipratropium provides bronchodilation without significant tachycardia, making it useful for patients who cannot tolerate β‑agonists. It is often combined with β2‑agonists for additive effect, offering a complementary mechanism that can improve symptom control in COPD and asthma.

Ipravent Inhaler should be stored at room temperature, preferably below 25 °C, in its original packaging to protect it from moisture and excessive heat. Keep the inhaler away from direct sunlight and do not expose it to freezing conditions. Proper storage helps maintain the stability and efficacy of the medication throughout its shelf life.

The inhaler is a metered‑dose device that delivers a measured spray of ipratropium bromide directly to the lungs. The patient should shake the inhaler, exhale fully, place the mouthpiece in the mouth, and press the canister while inhaling slowly and deeply. After each puff, hold the breath for a few seconds to allow optimal drug deposition before exhaling.

Although uncommon, serious adverse events can include paradoxical bronchospasm, which is a sudden worsening of breathing that requires immediate medical attention, and severe allergic reactions such as angioedema or anaphylaxis. Patients with narrow‑angle glaucoma may experience increased intra‑ocular pressure, and urinary retention can be problematic in susceptible individuals. Prompt reporting of any severe symptoms to a healthcare professional is essential.

Ipravent Inhaler is contraindicated in individuals with a known hypersensitivity to ipratropium bromide, atropine, or any other components of the formulation. It should also be avoided in patients with narrow‑angle glaucoma or those who have experienced paradoxical bronchospasm with anticholinergic inhalers. Clinicians must assess each patient’s medical history before initiating therapy to ensure safe use.